Recent Updates
Recently added Catalysts

STAR-0215

Phase 2

Hereditary Angioedema | Small molecule | Immunology |Astria Therapeutics, Inc.|Last Updated: Jul 23, 2025

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedDouble-BlindCONTROLLEDDMC
Total Trials2
Total Enrollment97
FDA Designations
No designations recorded
Clinical trial landscape

STAR-0215 · 2 trials · 1 indication

Phase 2 1Phase 1 1
NCT06007677A Long-term Study of STAR-0215 in Participants With Hereditary AngioedemaHereditary Angioedema
ACTIVE NOT_RECRUITING56 Analytics
PHASE2ACTIVE NOT_RECRUITING
A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema
Hereditary Angioedema
NCT0600767756
Unlock trial analytics
Study Endpoints
Primary Endpoints
Number of Participants Experiencing Treatment-emergent Adverse Events
Day 1 through study completion, an average of 6 years
Secondary Endpoints
Change From Baseline in Monthly HAE Attack Rate
Day 1, up to 5 years
Severity of HAE Attacks Experienced by Participants
Day 1 through up to 5 years
Duration of HAE Attacks
Day 1 through up to 5 years
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Dose Regimen 1 (Arm A): STAR-0215EXPERIMENTALParticipants will receive STAR-0215 every 3 months.
Dose Regimen 2 (Arm B): STAR-0215EXPERIMENTALParticipants will receive STAR-0215 every 6 months.
Dose Regimen 1 (Arm C): STAR-0215EXPERIMENTALSTAR-0215 will be administered as a subcutaneous injection.
Dose Regimen 3 (Arm D): STAR-0215EXPERIMENTALSTAR-0215 will be administered as a subcutaneous injection.
STAR-0215 Dose 1EXPERIMENTALParticipants will be randomized to receive STAR-0215 or placebo.
STAR-0215 Dose 2EXPERIMENTALParticipants will be randomized to receive STAR-0215 or placebo.
STAR-0215 Dose 3EXPERIMENTALParticipants will be randomized to receive STAR-0215 or placebo.
STAR-0215 Dose 4EXPERIMENTALParticipants will be randomized to receive STAR-0215 or placebo.
STAR-0215 Dose 5EXPERIMENTALParticipants will be randomized to receive STAR-0215 or placebo.
Interventions
NameTypeDescription
STAR-0215DRUGSTAR-0215 will be administered as a subcutaneous injection.
STAR-0215 (SC)DRUGSTAR-0215 will be administered as an SC bolus injection.
Placebo (SC)DRUGPlacebo will be administered as an SC bolus injection.
STAR-0215 (IV)DRUGSTAR-0215 will be administered as an IV bolus injection.
Placebo (IV)DRUGPlacebo will be administered as an IV bolus injection.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites22

Inclusion Criteria: * Open to participants from STAR-0215-201 (NCT05695248) who have met one of the following conditions: * Completed STAR-0215-201 (follow up through 6 months after their last dose); * Eligible for STAR-0215-201 and entered the Run-In period but did not qualify for the Treatme...

Countries:United StatesBulgariaCanadaCzechiaGermanyPolandUnited Kingdom
Unlock Eligibility Criteria
Competitive Landscape -Hereditary Angioedema 9 trials
CompanyTickerTrialsLead PhaseDrugs
Intellia Therapeutics, Inc.NTLA3PHASE3NTLA-2002, Normal Saline Administration
BioCryst Pharmaceuticals, Inc.BCRX2PHASE3Berotralstat
Ionis Pharmaceuticals, Inc.IONS1PHASE3Donidalorsen
Pharvaris N.V.PHVS1PHASE2deucrictibant
BioMarin Pharmaceutical Inc.BMRN1PHASE1Dose 1 of BMN 331
Astria Therapeutics, Inc.ATXS1PHASE2STAR-0215
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT06007677primaryCompletionDate: changed
LOWMay 24, 2026NCT06007677studyFirstPostDate: changed